# Gilead Sciences has agreed to buy German clinical-stage biotechnology company Tubulis.

*biotech · news · 2026-04-07 · MarketScreener*

## Key points

- Gilead Sciences will acquire Tubulis for up to $5 billion, including $3.15 billion upfront.
- Tubulis' lead asset, TUB-040, is in Phase 1b/2 trials for ovarian and lung cancer.
- The acquisition includes TUB-030, an ADC with promising early data in various solid tumors.
- Gilead will fund the Tubulis deal with cash on hand and senior unsecured notes.

**Companies:** Gilead Sciences, Tubulis
**Countries:** Germany, United States

[Read the full story on MarketScreener](https://www.marketscreener.com/news/gilead-sciences-to-buy-clinical-stage-biotech-tubulis-for-up-to-5-billion-update-ce7e51d3d188ff27)

---

Canonical: https://newsio.io/n/262f81f2-c20d-4a3d-b18a-5aca54e8d466/gilead-sciences-has-agreed-to-buy-german-clinical-stage-biotechnology-company-tu
Summarized by Newsio from MarketScreener. https://newsio.io/how-it-works